The junior biotech and drug discovery company rallied to a year high after saying it had entered into an exclusive agreement with Teva Pharmaceuticals, a top 20 global pharmaceutical group. The deal will see Teva help develop and commercialise Antisense's second-generation inhibitor, which has undergone trials for the treatment of multiple sclerosis. Under the terms of the deal, Antisense will receive an initial $US2 million ($2.2 million)payment and also has the potential to receive further payments related to the successful development of its technology. The deal with Teva covers potential milestone payments of up to $US100 million for the MS treatment, which is contingent upon research and development and sales.